- Home
- RMAX vs BIOA Comparison
RMAX vs BIOA Comparison
Compare RMAX & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$18.49
Company Overview
Basic Information| Metric | RMAX | BIOA |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | United States | United States |
| Employees | N/A | 64 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.5M | 856.3M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMAX | BIOA |
|---|---|---|
| Price | $5.72 | $18.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.00 | ★ $51.80 |
| AVG Volume (30 Days) | 241.8K | ★ 494.6K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $195,929,000.00 | N/A |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $1.15 | $898.47 |
| P/E Ratio | $9.72 | ★ N/A |
| Revenue Growth | ★ 11.13 | N/A |
| 52 Week Low | $5.66 | $2.88 |
| 52 Week High | $10.32 | $24.00 |
Technical Indicators
Market Signals| Indicator | RMAX | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 26.42 | 40.90 |
| Support Level | N/A | $18.62 |
| Resistance Level | $8.47 | $23.50 |
| Average True Range (ATR) | 0.25 | 1.29 |
| MACD | -0.02 | -0.37 |
| Stochastic Oscillator | 8.25 | 5.91 |
Price Performance
Historical Comparison RMAX
BIOA
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.